
Premium content
Access to this content requires a subscription. You must be a premium user to view this content.

poster
Association Between Lithium Usage and Skin and Subcutaneous Tissue Disorders: Analysis of FAERS Data
Introduction: A commonly used treatment for bipolar disorder is lithium which can cause numerous adverse events due to its low therapeutic index. Though, the literature poorly documents the association between lithium and skin and subcutaneous tissue disorders. To form targeted monitoring and management strategies understanding the distribution and trends of these adverse events in patients using lithium is crucial. The study aims to comprehensively analyze the association between lithium usage and the occurrence of skin and subcutaneous tissue disorders by utilizing data from the FDA Adverse Event Reporting System (FAERS).
Methods: A comprehensive search was performed on FAERS for skin and subcutaneous tissue disorder adverse events due to lithium usage reported from 1973 to 2024. Adverse events were categorized by sex, age group, reporter region, and reporter type. To provide a comprehensive overview of the distribution and trends of these adverse events descriptive statistics and trend analysis were employed.
Results: A total of 782 cases of skin and subcutaneous tissue disorders were associated with lithium usage. The distribution by sex revealed a higher number of cases in females (412) compared to males (305), with a smaller proportion of cases in unspecified categories (65). Age group analysis demonstrated that most cases (484) occurred in the 18-64 age group, with a notable concentration in adults. Geographically, the cases were nearly evenly distributed between domestic (384) and foreign (396) reports. Reporter-type analysis indicated that healthcare professionals reported most cases (499), followed by consumers (229) and a small number of unspecified sources (54).
Conclusion: The findings of this study highlight that skin and subcutaneous tissue disorders associated with lithium usage are more frequently reported in females and adults aged 18-64 years, with healthcare professionals being the primary reporters of these adverse events. These results underscore the importance of targeted monitoring and management strategies for patients on lithium therapy, mainly focusing on demographic groups at higher risk. Further research is warranted to explore the underlying mechanisms and develop preventive measures for these adverse events.